Applications and Advances of Metabolomics in Lung Cancer Research.
10.3779/j.issn.1009-3419.2025.106.20
- Author:
Daoyun WANG
1
;
Zhicheng HUANG
1
;
Bowen LI
1
;
Yadong WANG
1
;
Zhina WANG
2
;
Nan ZHANG
2
;
Zewen WEI
3
;
Naixin LIANG
1
;
Shanqing LI
1
Author Information
1. Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking
Union Medical College, Beijing 100730, China.
2. Department of Pulmonary and Critical Care Medicine, Emergency General
Hospital, Beijing 100028, China.
3. Department of Biomedical Engineering, School of Medical Technology,
Beijing Institute of Technology, Beijing 100081, China.
- Publication Type:English Abstract
- Keywords:
Drug resistance;
Lung neoplasms;
Metabolic reprogramming;
Metabolomics
- MeSH:
Humans;
Metabolomics/methods*;
Lung Neoplasms/pathology*;
Animals;
Biomarkers, Tumor/metabolism*
- From:
Chinese Journal of Lung Cancer
2025;28(7):533-541
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer, particularly non-small cell lung cancer (NSCLC), is a leading cause of cancer-related mortality worldwide. In recent years, metabolomics has emerged as a key systems biology approach for analyzing small-molecule metabolites in cells, tissues and organisms. It provides new strategies for early diagnosis and metabolic profiling. Additionally, metabolomics plays a crucial role in studying resistance mechanisms in lung cancer. Tumor cell metabolic reprogramming is a key driving factor in the initiation and progression of lung cancer. Metabolomics studies have revealed how lung cancer cells regulate critical pathways such as energy metabolism, lipid metabolism, and amino acid metabolism to adapt to the demands of rapid proliferation and invasive metastasis. This review summarizes the latest advances in metabolomics research in lung cancer, focusing on the characteristics of metabolic reprogramming, the identification of potential metabolic biomarkers, and the prospects of metabolomics in early diagnosis and the elucidation of resistance mechanisms in lung cancer.
.
